Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2010 /
The role of radiotherapy in the treatment of prostate cancer

7th - 10th Nov 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.01.11
Views: 5345

Prof Malcolm Mason - Cardiff University, UK

Prof Malcolm Mason discusses the results of an intergroup study - carried out by the UK Medical Research Council (MRC), the National Cancer Institute of Canada (NCIC) and the Southwest Oncology Group (SWOG) from the United States - looking at patients with locally advanced prostate cancer or high risk localised prostate cancer who would normally be treated with androgen deprivation therapy (ADT). This trial compared ADT alone with ADT plus radiotherapy and conclusively demonstrated the benefit of adding radiotherapy to ADT. Prof Mason speaks about the level of side effects experienced by the patients and looks forward to the results of the ongoing NCRI CHHIP study into hypofractionated radiotherapy.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation